New PNH drug iptacopan tested in Real-World chinese study
NCT ID NCT06931691
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well the drug iptacopan works for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Researchers will track changes in hemoglobin levels and other health outcomes in 80 patients across China. The goal is to see if iptacopan improves disease control and reduces the need for healthcare resources.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGHefei, Anhui, 230022, China
-
Novartis Investigative Site
RECRUITINGGuangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
RECRUITINGGuangzhou, Guangdong, 510080, China
-
Novartis Investigative Site
RECRUITINGShijiazhuang, Hebei, 050000, China
-
Novartis Investigative Site
RECRUITINGZhengzhou, Henan, 450003, China
-
Novartis Investigative Site
RECRUITINGZhengzhou, Henan, 450008, China
-
Novartis Investigative Site
RECRUITINGWuhan, Hubei, 430030, China
-
Novartis Investigative Site
RECRUITINGNantong, Jiangsu, 226000, China
-
Novartis Investigative Site
RECRUITINGNanchang, Jiangxi, 330006, China
-
Novartis Investigative Site
RECRUITINGChangchun, Jilin, 130021, China
-
Novartis Investigative Site
RECRUITINGJinan, 250012, China
-
Novartis Investigative Site
RECRUITINGTianjin, 300020, China
-
Novartis Investigative Site
RECRUITINGTianjin, 300052, China
-
Novartis Investigative Site
RECRUITINGWuhan, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Every-8-Week shot could simplify PNH treatment
- Real-World test: can a targeted drug keep PNH in check for years?
- New transplant method aims to reduce complications in bone marrow failure patients
- No treatment, just observation: large study looks at PNH blood cells
- New hope for rare blood disorder: Long-Term study of XH-S003 underway
- New transplant approach aims to tame bone marrow failure